<p>Ovarian cancer is a highly lethal malignancy of the female reproductive system, characterized by a poor prognosis and complex therapeutic challenges influenced by various molecular and microenvironmental factors. Among these, mutations in the <i>BRAF</i> gene have received increasing attention across multiple malignancies due to their involvement in oncogenic signaling pathways and implications for targeted therapy. Concurrently, the tumor immune microenvironment has been recognized as a critical determinant in the initiation and progression of tumors. This review explores the impact of <i>BRAF</i> mutations on the immune microenvironment in ovarian cancer, summarizes recent advances in the field, and assesses the potential clinical significance of these findings in informing therapeutic strategies.</p><p> <?qj left?> <?noindent??><i>Clinical trial number</i>: Not applicable.</p>